Advertisement

Corticosteroide

  • Ulrich Schwabe

Zusammenfassung

Corticosteroide werden überwiegend als Glucocorticoide zur Entzündungshemmung und Immunsuppression eingesetzt, während die Hormonsubstitution mit dem Nebennierenrindenhormon Cortisol und dem Mineralocorticoid Fludrocortison nur einen kleinen Teil der Verordnungen (3%) betrifft.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2005): Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 19(2): CD005328Google Scholar
  2. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R (2008) : Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371: 205–214PubMedCrossRefGoogle Scholar
  3. Huppertz HI, Pfuller H (1997): Transient suppression of endogenous cortisol production after intraarticular steroid therapy for chronic arthritis in children. J Rheumatol 24: 1833–1837PubMedGoogle Scholar
  4. Kamada AK, Wiener MB, LaVallee NM, Bartoszek SM., Selner JC, Szefler SJ (1997): A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. Pharmacotherapy 17: 353–356PubMedGoogle Scholar
  5. Köbberling J (1979): Gefahren der Depotkortikoid-Therapie. Internist Welt 4: 118–122Google Scholar
  6. Lanier JB, Mote MB, Clay EC (2011): Evaluation and management of orthostatic hypotension. Am Fam Physician 84: 527–536Google Scholar
  7. Medici TC, Rüegsegger P (1990): Does alternate-day cloprednol therapy prevent bone loss? A longitudinal double-blind, controlled clinical study. Clin Pharmacol Ther 48: 455–466PubMedCrossRefGoogle Scholar
  8. Mygind N, Laursen LC, Dahl M (2000): Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. Allergy 55: 11–15PubMedGoogle Scholar
  9. Nasser SMS, Ewan PW (2001): Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. BMJ 322: 1589–1591PubMedCentralPubMedCrossRefGoogle Scholar
  10. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka- Isler T, Wong JB, van der Heijde D (2014): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492–509PubMedCentralPubMedGoogle Scholar
  11. Strehl C, Buttgereit F (2013): Optimized glucocorticoid therapy: teaching old drugs new tricks. Mol Cell Endocrinol 380: 32–40PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches InstitutUniversität HeidelbergHeidelberg

Personalised recommendations